Craig Nelson, PhD
University of Connecticut - Storrs, CT
Associate Professor, Molecular and Cell Biology
Thomas Peters, PhD
University of Connecticut - Storrs, CT
Professor, Computer Science and Engineering & Mathematics
Richard H. Fortinsky, Ph.D.
UConn Health - Farmington, CT
Professor & Health Net, Inc. Chair in Geriatrics & Gerontology
Marc R. Del Bigio, MD PhD FRCPC
Max Rady College of Medicine - Manitoba, Canada
Professor, Department of Pathology
Prof. Dr. h.c. Eberhard Bodenschatz
Max Planck Institute for Dynamics
and Self-Organization - Göttingen, Germany
Laboratory for Fluid Dynamics, Pattern Formation and Biocomplexity (LFPB);
Kristopher Thomas Kahle, MD, PhD
Yale University - New Haven, CT
Assistant Professor of Neurosurgery; Pediatrics, and Cellular and Molecular Physiology; Director, Neonatal and Congenital Anomaly Neurosurgery
Dr. Ketan R. Bulsara, MD, MBA
UConn Health - Farmington, CT
Chief of Division of Neurosurgery, Director of Neurovascular and Endovascular Surgery, Director of Skull Base Microsurgery
Donald M. Kuhn, PhD
Wayne State University School of Medicine & John D. Dingell VA Medical Center (11R) - Detroit, MI
Professor, Department of Psychiatry & Behavioral Neurosciences;
Alzheimer’s Disease Neuroimaging Initiative (ADNI)
The ADNI was launched in 2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early Alzheimer’s disease (AD). For up-to-date information, see www.adni-info.org.
ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics.
The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.
The Baltimore Longitudinal Study of Aging (BLSA)
The BLSA (www.blsa.nih.gov) is a comprehensive, observational longitudinal study that measures changes associated with the aging process in an effort to identify targets for the prevention of age-related disease. Our key collaborators at the BLSA include Susan Resnick, Wendy Elkins, Juan Troncoso, and Olga Pletnikova. The BLSA is supported by the Intramural Research Program, NIA, NIH.